Creating order from chaos: Cellular regulation by kinase anchoring

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 187-210

  Scott, John D ^a   Dessauer, Carmen W ^b   Taskén, Kjetil ^c,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

A kinase anchoring proteins; cAMP; cell signaling; compartmentalization; protein phosphorylation

Indexed keywords

ADENYLATE CYCLASE; CALCIUM; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; NUCLEAR PROTEIN; PHOSPHODIESTERASE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN AKAP LBC; PROTEIN AKAP150; PROTEIN AKAP18 ALPHA; PROTEIN AKAP79; PROTEIN KINASE; PROTEIN MAKAP; SPHINGOSINE KINASE; UNCLASSIFIED DRUG;

CALCIUM SIGNALING; CALCIUM TRANSPORT; CARDIOVASCULAR SYSTEM; CELL FUNCTION; ENZYME BINDING; ENZYME LOCALIZATION; HEART REPOLARIZATION; HEART STRESS; HUMAN; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW;

A KINASE ANCHOR PROTEINS; ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; IMMUNE SYSTEM; PROTEIN KINASES; SECOND MESSENGER SYSTEMS;

EID: 84872233315     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011112-140204     Document Type: Review

References (198)

1. Rall TW, Sutherland EW, Berthet J. 1957. The relationships of epinephrine and glucagon to liver phosphorylase. J. Biol. Chem. 224:463-75
2. Sutherland EW. 1972. Studies on the mechanism of hormone action. Science 171:401-8
3. Fischer EH, Krebs EG. 1955. Conversion of phosphorylase b to phosphorylase a in muscle extracts. J. Biol. Chem. 216:121-32
4. Corbin JD, Soderling TR, Park CR. 1973. Regulation of adenosine 3′,5′-monophosphate-dependent protein kinase. J. Biol. Chem. 248:1813-21
5. Potter RL, Stafford PH, Taylor S. 1978. Regulatory subunit of cyclic AMP-dependent protein kinase I from porcine skeletal muscle: purification and proteolysis. Arch. Biochem. Biophys. 190:174-80
6. Kemp BE, Benjamini E, Krebs EG. 1976. Synthetic hexapeptide substrates and inhibitors of 3′-5′-cyclic AMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA 73:1038-42
7. Keely SL. 1977. Activation of cAMP-dependent protein kinase without a corresponding increase in phosphorylase activity. Res. Commun. Chem. Pathol. Pharmacol. 18:283-90
8. Hayes JS, Brunton LL, Brown JH, Reese JB, Mayer SE. 1979. Hormonally specific expression of cardiac protein kinase activity. Proc. Natl. Acad. Sci. USA 76:1570-74
9. Brunton LL, Hayes JS, Mayer SE. 1979. Hormonally specific phosphorylation of cardiac troponin I and activation of glycogen phosphorylase. Nature 280:78-80
10. Corbin JD, Sugden PH, Lincoln TM, Keely SL. 1977. Compartmentalization of adenosine 3′-5′-monophosphate and adenosine 3′-5′- monophosphate-dependent protein kinase in heart tissue. J. Biol. Chem. 252:3854-61
11. Theurkauf WE, Vallee RB. 1982. Molecular characterization of the cAMP-dependent protein kinase bound to microtubule-associated protein 2. J. Biol. Chem. 257:3284-90
12. Sarkar D, Erlichman J, Rubin CS. 1984. Identification of a calmodulin-binding protein that co-purifies with the regulatory subunit of brain protein kinase II. J. Biol. Chem. 259:9840-46
13. Lohmann SM, DeCamili P, Enig I, Walter U. 1984. High-affinity binding of the regulatory subunit (RII) of cAMP-dependent protein kinase to microtubule-associated and other cellular proteins. Proc. Natl. Acad. Sci. USA 81:6723-27
14. Carr DW, Scott JD. 1992. Blotting and band-shifting: techniques for studying protein-protein interactions. Trends Biochem. Sci. 17:246-49
15. Alto NM, Soderling J, Scott JD. 2002. Rab32 is an A-kinase anchoring protein and participates in mitochondrial dynamics. J. Cell Biol. 158:659-68
16. Pidoux G, Tasḱen K. 2010. Specificity and spatial dynamics of protein kinase A signaling organized by A-kinase-anchoring proteins. J. Mol. Endocrinol. 44:271-84
17. Wong W, Scott JD. 2004. AKAP signalling complexes: focal points in space and time. Nat. Rev. Mol. Cell Biol. 5:959-70
18. Scott JD, Stofko RE,McDonald JR, Comer JD, Vitalis EA,Mangeli J. 1990. Type II regulatory subunit dimerization determines the subcellular localization of the cAMP-dependent protein kinase. J. Biol. Chem. 265:21561-66
19. Carr DW,Hausken ZE, Fraser IDC, Stofko-Hahn RE, Scott JD. 1992. Association of the type II cAMPdependent protein kinase with a human thyroid RII-anchoring protein: cloning and characterization of the RII-binding domain. J. Biol. Chem. 267:13376-82
20. Carr DW, Stofko-Hahn RE, Fraser IDC, Bishop SM, Acott TS, et al. 1991. Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J. Biol. Chem. 266:14188-92
21. Rosenmund C, Carr DW, Bergeson SE, Nilaver G, Scott JD, Westbrook GL. 1994. Anchoring of protein kinase A is required for modulation of AMPA/kainate receptors on hippocampal neurons. Nature 368:853-56
22. Coghlan VM, Perrino BA, Howard M, Langeberg LK, Hicks JB, et al. 1995. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. Science 267:108-11
23. Klauck TM, Faux MC, Labudda K, Langeberg LK, Jaken S, Scott JD. 1996. Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein. Science 271:1589-92
24. Scott JD, Pawson T. 2009. Cell signaling in space and time: where proteins come together and when they're apart. Science 326:1220-24
25. Sanderson JL, Dell'Acqua ML. 2011. AKAP signaling complexes in regulation of excitatory synaptic plasticity. Neuroscientist 17:321-36
26. Kritzer MD, Li J, Dodge-Kafka K, Kapiloff MS. 2012. AKAPs: the architectural underpinnings of local cAMP signaling. J. Mol. Cell. Cardiol. 52:351-58
27. Greenwald EC, Saucerman JJ. 2011. Bigger, better, faster: principles and models of AKAP anchoring protein signaling. J. Cardiovasc. Pharmacol. 58:462-69
28. Diviani D, Langeberg LK, Doxsey SJ, Scott JD. 2000. Pericentrin anchors protein kinase A at the centrosome through a newly identified RII-binding domain. Curr. Biol. 10:417-20
29. Hausken ZE, Coghlan VM,Hasting CAS, Reimann EM, Scott JD. 1994. Type II regulatory subunit (RII) of the cAMP-dependent protein kinase interaction with A-kinase anchor proteins requires isoleucines 3 and 5. J. Biol. Chem. 269:24245-51
30. Herberg FW, Maleszka A, Eide T, Vossebein L, Tasḱen K. 2000. Analysis of A-kinase anchoring protein (AKAP) interaction with protein kinase A (PKA) regulatory subunits: PKA isoform specificity in AKAP binding. J. Mol. Biol. 298:329-39
31. Ruppelt A, Mosenden R, Gronholm M, Aandahl EM, Tobin D, et al. 2007. Inhibition ofTcell activation by cyclic adenosine 5′-monophosphate requires lipid raft targeting of protein kinase A type I by the Akinase anchoring protein ezrin. J. Immunol. 179:5159-68
32. Pidoux G, Witczak O, Jarnaess E, Myrvold L, Urlaub H, et al. 2011. Optic atrophy 1 is an A-kinase anchoring protein on lipid droplets that mediates adrenergic control of lipolysis. EMBO J. 30:4371-86
33. Means CK, Lygren B, Langeberg LK, Jain A, Dixon RE, et al. 2011. An entirely specific type I A-kinase anchoring protein that can sequester twomolecules of protein kinase A at mitochondria. Proc. Natl. Acad. Sci. USA 108:E1227-35
34. Newlon MG, Roy M, Morikis D, Carr DW, Westphal R, et al. 2001. A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes. EMBO J. 20:1651-62
35. Newlon MG, Roy M, Morikis D, Hausken ZE, Coghlan V, et al. 1999. The molecular basis for protein kinase A anchoring revealed by solution NMR. Nat. Struct. Biol. 6:222-27
36. Gold MG, Lygren B, Dokurno P, Hoshi N, McConnachie G, et al. 2006. Molecular basis of AKAP specificity for PKA regulatory subunits. Mol. Cell 24:383-95
37. Kinderman FS, Kim C, von Daake S, Ma Y, Pham BQ, et al. 2006. A dynamic mechanism for AKAP binding to RII isoforms of cAMP-dependent protein kinase. Mol. Cell 24:397-408
38. Banky P, Huang LJ, Taylor SS. 1998. Dimerization/docking domain of the type Iα regulatory subunit of cAMP-dependent protein kinase: Requirements for dimerization and docking are distinct but overlapping. J. Biol. Chem. 273:35048-55
39. Banky P, Newlon MG, Roy M, Garrod S, Taylor SS, Jennings PA. 2000. Isoform-specific differences between the type Iα and IIα cyclic AMP-dependent protein kinase anchoring domains revealed by solution NMR. J. Biol. Chem. 275:35146-52
40. Lester LB, Langeberg LK, Scott JD. 1997. Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. Proc. Natl. Acad. Sci. USA 94:14942-47
41. Johnson BD, Scheuer T, Catterall WA. 1994. Voltage-dependent potentiation of L-type Ca2+ channels in skeletal muscle cells requires anchored cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA 91:11492-96
42. Fraser IDC, Tavalin SJ, Lester LB, Langeberg LK, Westphal AM, et al. 1998. A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events. EMBO J. 17:2261-72
43. Vijayaraghavan S,Goueli SA,Davey MP,CarrDW. 1997. Protein kinase A-anchoring inhibitor peptides arrest mammalian sperm motility. J. Biol. Chem. 272:4747-52
44. Fink MA, Zakhary DR, Mackey JA, Desnoyer RW, Apperson-Hansen C, et al. 2001. AKAP-mediated targeting of protein kinase A regulates contractility in cardiac myocytes. Circ. Res. 88:291-97
45. Gold MG, Reichow SL, O'Neill SE, Weisbrod CR, Langeberg LK, et al. 2012. AKAP2 anchors PKA with aquaporin-0 to support ocular lens transparency. EMBO Mol. Med. 4:15-26
46. Alto NM, Soderling SH, Hoshi N, Langeberg LK, Fayos R, et al. 2003. Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring. Proc. Natl. Acad. Sci. USA 100:4445-50
47. Burns-Hamuro LL, Ma Y, Kammerer S, Reineke U, Self C, et al. 2003. Designing isoform-specific peptide disruptors of protein kinase A localization. Proc. Natl. Acad. Sci. USA 100:4072-77
48. Carlson CR, Lygren B, Berge T, Hoshi N, Wong W, et al. 2006. Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J. Biol. Chem. 281:21535-45
49. Torheim EA, Ndhlovu LC, Pettersen FO, Larsen TL, Jha AR, et al. 2009. Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. Eur. J. Immunol. 39:1280-87
50. Mosenden R, Singh P, Cornez I, Heglind M, Ruppelt A, et al. 2011. Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced immunodeficiency. J. Immunol. 186:5119-30
51. McKenzie AJ, Campbell SL, Howe AK. 2011. Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion. PLoS ONE 6:e26552
52. Di Benedetto G, Zoccarato A, Lissandron V, Terrin A, Li X, et al. 2008. Protein kinase A type I and type II define distinct intracellular signaling compartments. Circ. Res. 103:836-44
53. Jarnaess E, Ruppelt A, Stokka AJ, Lygren B, Scott JD, Tasḱen K. 2008. Dual specificity A-kinase anchoring proteins (AKAPs) contain an additional binding region that enhances targeting of protein kinase A type I. J. Biol. Chem. 283:33708-18
54. Lygren B, Carlson CR, Santamaria K, Lissandron V, McSorley T, et al. 2007. AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep. 8:1061-67
55. Stokka AJ, Mosenden R, Ruppelt A, Lygren B, Tasḱen K. 2010. The adaptor protein EBP50 is important for localization of the protein kinase A-Ezrin complex in T-cells and the immunomodulating effect of cAMP. Biochem. J. 425:381-88
56. Bers DM. 2008. Calcium cycling and signaling in cardiac myocytes. Annu. Rev. Physiol. 70:23-49
57. Sadana R, Dessauer CW. 2009. Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. NeuroSignals 17:5-22
58. Willoughby D, Cooper DMF. 2007. Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol. Rev. 87:965-1010
59. Ostrom RS, Naugle JE, Hase M, Gregorian C, Swaney JS, et al. 2003. Angiotensin II enhances adenylyl cyclase signaling via Ca2+/calmodulin: Gq-Gs cross-talk regulates collagen production in cardiac fibroblasts. J. Biol. Chem. 278:24461-68
60. Iwatsubo K, Minamisawa S, Tsunematsu T, Nakagome M, Toya Y, et al. 2004. Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J. Biol. Chem. 279:40938-45
61. Okumura S, Kawabe J, Yatani A, Takagi G, Lee MC, et al. 2003. Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ. Res. 93:364-71
62. Guellich A, Gao S, Hong C, Yan L, Wagner TE, et al. 2010. Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload. Am. J. Physiol. Heart Circ. Physiol. 299:H707-12
63. Takahashi T, Tang T, Lai NC, Roth DM, Rebolledo B, et al. 2006. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation 114:388-96
64. Gao MH, Tang T, Guo T,Miyanohara A, Yajima T, et al. 2008. Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes. J. Biol. Chem. 283:33527-35
65. Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H, et al. 2007. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 130:247-58
66. Hu CL, Chandra R, Ge H, Pain J, Yan L, et al. 2009. Adenylyl cyclase type 5 protein expression during cardiac development and stress. Am. J. Physiol. Heart Circ. Physiol. 297:H1776-82
67. Tang T, Gao MH, Lai NC, Firth AL, Takahashi T, et al. 2008. Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling. Circulation 117:61-69
68. Burton KA, Johnson BD, Hausken ZE, Westenbroek RE, Idzerda RL, et al. 1997. Type II regulatory subunits are not required for the anchoring-dependent modulation of Ca2+ channel activity by cAMPdependent protein kinase. Proc. Natl. Acad. Sci. USA 94:11067-72
69. Gao TY, Yatani A, Dell'Acqua ML, Sako H, Green SA, et al. 1997. cAMP-dependent regulation of cardiac L-type Ca2+ channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron 19:185-96
70. Kockskamper J, Sendhoff K, Erlenkamp S, Bordusa F, Cerovsky V, Glitsch HG. 2001. Differences in the protein-kinase-A-dependent regulation of CFTR Cl? channels and Na+-K+ pumps in guinea-pig ventricular myocytes. Pfl̈ ug. Arch. 441:807-15
71. Potet F, Scott JD, Mohammad-Panah R, Escande D, Baro I. 2001. AKAP proteins anchor cAMPdependent protein kinase to KvLQT1/IsK channel complex. Am. J. Physiol. Heart Circ. Physiol. 280:H2038-45
72. Fink MA, Zakhary DR, Mackey JA, Desnoyer RW, Apperson-Hansen C, et al. 2001. AKAP-mediated targeting of protein kinase A regulates contractility in cardiac myocytes. Circ. Res. 88:291-97
73. McConnell BK, Popovic Z, Mal N, Lee K, Bautista J, et al. 2009. Disruption of protein kinase A interaction with A-kinase-anchoring proteins in the heart in vivo: effects on cardiac contractility, protein kinase A phosphorylation, and troponin I proteolysis. J. Biol. Chem. 284:1583-92
74. Patel HH, Hamuro LL, Chun BJ, Kawaraguchi Y, Quick A, et al. 2010. Disruption of protein kinase A localization using a trans-activator of transcription (TAT)-conjugated A-kinase-anchoring peptide reduces cardiac function. J. Biol. Chem. 285:27632-40
75. Diviani D, Scott JD. 2001. AKAP signaling complexes at the cytoskeleton. J. Cell Sci. 114:1431-37
76. Malbon CC, Tao J,WangHY. 2004. AKAPs (A-kinase anchoring proteins) and molecules that compose their G-protein-coupled receptor signalling complexes. Biochem. J. 379:1-9
77. Navedo MF, Cheng EP, Yuan C, Votaw S,Molkentin JD, et al. 2010. Increased coupled gating of L-type Ca2+ channels during hypertension and Timothy syndrome. Circ. Res. 106:748-56
78. Gray PC, Johnson BD, Westenbroek RE, Hays LG, Yates JR III, et al. 1998. Primary structure and function of an A kinase anchoring protein associated with calcium channels. Neuron 20:1017-26
79. Trotter KW, Fraser IDC, Scott GK, Stutts MJ, Scott JD, Milgram SL. 1999. Alternative splicing regulates the subcellular localization of A-kinase anchoring protein 18 isoforms. J. Cell Biol. 147:1481-92
80. Henn V, Edemir B, Stefan E, Wiesner B, Lorenz D, et al. 2004. Identification of a novel A-kinase anchoring protein 18 isoform and evidence for its role in the vasopressin-induced aquaporin-2 shuttle in renal principal cells. J. Biol. Chem. 279:26654-65
81. Hulme JT, LinTW,Westenbroek RE, ScheuerT,CatterallWA.2003.β- Adrenergic regulation requires direct anchoring of PKA to cardiac CaV1.2 channels via a leucine zipper interaction with A kinaseanchoring protein 15. Proc. Natl. Acad. Sci. USA 100:13093-98
82. Hulme JT, AhnM,Hauschka SD, ScheuerT,CatterallWA.2002.Anovel leucine zipper targetsAKAP15 and cyclic AMP-dependent protein kinase to the C terminus of the skeletal muscle Ca2+ channel and modulates its function. J. Biol. Chem. 277:4079-87
83. Hulme JT, Westenbroek RE, Scheuer T, Catterall WA. 2006. Phosphorylation of serine 1928 in the distal C-terminal domain of cardiac CaV1.2 channels during β1-adrenergic regulation. Proc. Natl. Acad. Sci. USA 103:16574-79
84. Fuller MD, Emrick MA, Sadilek M, Scheuer T, Catterall WA. 2010. Molecular mechanism of calcium channel regulation in the fight-or-flight response. Sci. Signal. 3:ra70
85. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, et al. 2003. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat. Genet. 35:131-38
86. Oliveria SF,Dell'Acqua ML, SatherWA. 2007. AKAP79/150 anchoring of calcineurin controls neuronal L-type Ca2+ channel activity and nuclear signaling. Neuron 55:261-75
87. Dell'Acqua ML, Faux MC, Thorburn J, Thorburn A, Scott JD. 1998. Membrane-targeting sequences on AKAP79 bind phosphatidylinositol-4, 5-bisphosphate. EMBO J. 17:2246-60
88. Delint-Ramirez I, Willoughby D, Hammond GVR, Ayling LJ, Cooper DMF. 2011. Palmitoylation targets AKAP79 protein to lipid rafts and promotes its regulation of calcium-sensitive adenylyl cyclase type 8. J. Biol. Chem. 286:32962-75
89. Bauman AL, Soughayer J, Nguyen BT, Willoughby D, Carnegie GK, et al. 2006. Dynamic regulation of cAMP synthesis through anchored PKA-adenylyl cyclase V/VI complexes. Mol. Cell 23:925-31
90. Tunquist BJ, Hoshi N, Guire ES, Zhang F, Mullendorff K, et al. 2008. Loss of AKAP150 perturbs distinct neuronal processes in mice. Proc. Natl. Acad. Sci. USA 105:12557-62
91. Navedo MF, Nieves-Cintr ́on M, Amberg GC, Yuan C, Votaw VS, et al. 2008. AKAP150 is required for stuttering persistent Ca2+ sparklets and angiotensin II-induced hypertension. Circ. Res. 102:e1-11
92. Gold MG, Stengel F, Nygren PJ,Weisbrod CR, Bruce JE, et al. 2011. Architecture and dynamics of an A-kinase anchoring protein 79 (AKAP79) signaling complex. Proc. Natl. Acad. Sci. USA 108:6426-31
93. Gao S,Wang H-y, Malbon C. 2011. AKAP5 and AKAP12 form homo-oligomers. J. Mol. Signal. 6:3
94. Gao S, Wang H-y, Malbon C. 2011. AKAP12 and AKAP5 form higher-order hetero-oligomers. J. Mol. Signal. 6:8
95. Fraser IDC, Cong M, Kim J, Rollins EN, Daaka Y, et al. 2000. Assembly of an A kinase-anchoring protein-β2-adrenergic receptor complex facilitates receptor phosphorylation and signaling. Curr. Biol. 10:409-12
96. Nichols CB, Rossow CF, Navedo MF, Westenbroek RE, Catterall WA, et al. 2010. Sympathetic stimulation of adult cardiomyocytes requires association of AKAP5 with a subpopulation of L-type calcium channels. Circ. Res. 107:747-56
97. Colledge M, Dean RA, Scott GK, Langeberg LK, Huganir RL, Scott JD. 2000. Targeting of PKA to glutamate receptors through a MAGUK-AKAP complex. Neuron 27:107-19
98. Nieves-Cintŕon M, Amberg GC, Navedo MF, Molkentin JD, Santana LF. 2008. The control of Ca2+ influx and NFATc3 signaling in arterial smooth muscle during hypertension. Proc. Natl. Acad. Sci. USA 105:15623-28
99. Nieves-Cintŕon M, Amberg GC, Nichols CB, Molkentin JD, Santana LF. 2007. Activation of NFATc3 down-regulates the β1 subunit of large conductance, calcium-activated K+ channels in arterial smooth muscle and contributes to hypertension. J. Biol. Chem. 282:3231-40
100. Westphal RS, Tavalin SJ, Lin JW, Alto NM, Fraser IDC, et al. 1999. Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex. Science 285:93-96
101. Schmidt PH, Dransfield DT, Claudio JO, Hawley RG, Trotter KW, et al. 1999. AKAP350, a multiply spliced protein kinase A-anchoring protein associated with centrosomes. J. Biol. Chem. 274:3055-66
102. Witczak O, Skalhegg BS, Keryer G, Bornens M, Tasḱen K, et al. 1999. Cloning and characterization of a cDNA encoding an A-kinase anchoring protein located in the centrosome, AKAP450. EMBO J. 18:1858-68
103. Terrenoire C, Houslay MD, Baillie GS, Kass RS. 2009. The cardiac IKs potassium channelmacromolecular complex includes the phosphodiesterase PDE4D3. J. Biol. Chem. 284:9140-46
104. Piggott LA, Bauman AL, Scott JD, Dessauer CW. 2008. The A-kinase anchoring protein Yotiao binds and regulates adenylyl cyclase in brain. Proc. Natl. Acad. Sci. USA 105:13835-40
105. Marx SO, Kurokawa J, Reiken S, Motoike H, D'Armiento J, et al. 2002. Requirement of amacromolecular signaling complex for β adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 295:496-99
106. Kurokawa J, Motoike HK, Rao J, Kass RS. 2004. Regulatory actions of the A-kinase anchoring protein Yotiao on a heart potassium channel downstream of PKA phosphorylation. Proc. Natl. Acad. Sci. USA 101:16374-78
107. Chen L, Kurokawa J, Kass RS. 2005. Phosphorylation of the A-kinase-anchoring protein Yotiao contributes to protein kinase A regulation of a heart potassium channel. J. Biol. Chem. 280:31347-52
108. Chen L, Marquardt ML, Tester DJ, Sampson KJ, Ackerman MJ, Kass RS. 2007. Mutation of an Akinase-anchoring protein causes long-QT syndrome. Proc. Natl. Acad. Sci. USA 104:20990-95
109. Lu JT, Kass RS. 2010. Recent progress in congenital longQT syndrome. Curr. Opin. Cardiol. 25:216-21
110. Kammerer S, Burns-Hamuro LL, Ma Y, Hamon SC, Canaves JM, et al. 2003. Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism. Proc. Natl. Acad. Sci. USA 100:4066-71
111. Tingley WG, Pawlikowska L, Zaroff JG, KimT, Nguyen T, et al. 2007. Gene-trappedmouse embryonic stem cell-derived cardiac myocytes and human genetics implicate AKAP10 in heart rhythm regulation. Proc. Natl. Acad. Sci. USA 104:8461-66
112. Wang L, Sunahara RK, Krumins A, Perkins G, Crochiere ML, et al. 2001. Cloning and mitochondrial localization of full-length D-AKAP2, a protein kinase A anchoring protein. Proc. Natl. Acad. Sci. USA 98:3220-25
113. Eggers CT, Schafer JC, Goldenring JR, Taylor SS. 2009. D-AKAP2 interacts with Rab4 and Rab11 through its RGS domains and regulates transferrin receptor recycling. J. Biol. Chem. 284:32869-80
114. Frey N, Olson EN. 2003. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65:45-79
115. ZhengY, Olson MF, Hall A, Cerione RA, Toksoz D. 1995. Direct involvement of the small GTP-binding protein Rho in lbc oncogene function. J. Biol. Chem. 270:9031-34
116. Diviani D, Soderling J, Scott JD. 2001. AKAP-Lbc anchors protein kinase A and nucleates Gα12-selective Rho-mediated stress fiber formation. J. Biol. Chem. 276:44247-57
117. Sah VP, Hoshijima M, Chien KR, Brown JH. 1996. Rho is required forGαq andα1-adrenergic receptor signaling in cardiomyocytes: dissociation of Ras and Rho pathways. J. Biol. Chem. 271:31185-90
118. Appert-Collin A, Cotecchia S, Nenniger-Tosato M, Pedrazzini T, Diviani D. 2007. The A-kinase anchoring protein (AKAP)-Lbc-signaling complex mediates α1 adrenergic receptor-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. USA 104:10140-45
119. Diviani D, Abuin L, Cotecchia S, Pansier L. 2004. Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex. EMBO J. 23:2811-20
120. Jin J, Smith FD, Stark C, Wells CD, Fawcett JP, et al. 2004. Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr. Biol. 14:1436-50
121. Carnegie GK, Soughayer J, Smith FD, Pedroja BS, Zhang F, et al. 2008. AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol. Cell 32:169-79
122. Carnegie GK, Smith FD, McConnachie G, Langeberg LK, Scott JD. 2004. AKAP-Lbc nucleates a protein kinase D activation scaffold. Mol. Cell 15:889-99
123. Smith FD, Langeberg LK, Cellurale C, Pawson T, Morrison DK, et al. 2010. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Nat. Cell Biol. 12:1242-49
124. Cariolato L, Cavin S, Diviani D. 2011. A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling complex involved inα1-adrenergic receptor-induced p38 activation. J. Biol. Chem. 286:7925-37
125. MayersCM, Wadell J, McLeanK, VenereM, Malik M, et al. 2010. TheRho guanine nucleotide exchange factor AKAP13 (BRX) is essential for cardiac development in mice. J. Biol. Chem. 285:12344-54
126. Kapiloff MS, Piggott LA, Sadana R, Li J, Heredia LA, et al. 2009. An adenylyl cyclase-mAKAPβsignaling complex regulates cAMP levels in cardiac myocytes. J. Biol. Chem. 284:23540-46
127. Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, et al. 2001. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J. 20:1921-30
128. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, et al. 2000.PKAphosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101:365-76
129. Carlisle Michel JJ, Dodge KL, Wong W, Mayer NC, Langeberg LK, Scott JD. 2004. PKAphosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem. J. 381:587-92
130. Kapiloff MS, Schillace RV, Westphal AM, Scott JD. 1999. mAKAP: an A-kinase anchoring protein targeted to the nuclear membrane of differentiated myocytes. J. Cell Sci. 112:2725-36
131. Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle Michel JJ, Langeberg LK, et al. 2005. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437:574-78
132. Zhang L, Malik S, Kelley GG, Kapiloff MS, Smrcka AV. 2011. Phospholipase Cε scaffolds to musclespecific A kinase anchoring protein (mAKAPβ) and integrates multiple hypertrophic stimuli in cardiac myocytes. J. Biol. Chem. 286:23012-21
133. Pare GC, Bauman AL, McHenry M, Carlisle Michel JJ, Dodge-Kafka KL, Kapiloff MS. 2005. The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling. J. Cell Sci. 118:5637-46
134. Dodge-Kafka KL, Bauman A, Mayer N, Henson E, Heredia L, et al. 2010. cAMP-stimulated protein phosphatase 2Aactivity associated with muscleAkinase-anchoring protein(mAKAP)signaling complexes inhibits the phosphorylation and activity of the cAMP-specific phosphodiesterasePDE4D3. J. Biol.Chem. 285:11078-86
135. Pare GC, Easlick JL, Mislow JM, McNally EM, Kapiloff MS. 2005. Nesprin-1α contributes to the targeting of mAKAP to the cardiac myocyte nuclear envelope. Exp. Cell Res. 303:388-99
136. Heather LC, Clarke K. 2011. Metabolism, hypoxia and the diabetic heart. J. Mol. Cell. Cardiol. 50:598-605
137. Wong W, Goehring AS, Kapiloff MS, Langeberg LK, Scott JD. 2008. mAKAP compartmentalizes oxygen-dependent control of HIF-1α. Sci. Signal. 1:ra18
138. Feliciello A, Rubin CS, Avvedimento EV, Gottesman ME. 1998. Expression of a kinase anchor protein 121 is regulated by hormones in thyroid and testicular germ cells. J. Biol. Chem. 273:23361-66
139. Huang LJ, Wang L, Ma Y, Durick K, Perkins G, et al. 1999.NH2-Terminal targeting motifs direct dual specificity A-kinase-anchoring protein 1 (D-AKAP1) to either mitochondria or endoplasmic reticulum. J. Cell Biol. 145:951-59
140. Chen Q, Lin RY, Rubin CS. 1997. Organelle-specific targeting of protein kinase AII (PKAII):molecular and in situ characterization of murine A kinase anchor proteins that recruit regulatory subunits of PKAII to the cytoplasmic surface of mitochondria. J. Biol. Chem. 272:15247-57
141. Abrenica B, AlShaaban M, Czubryt MP. 2009. The A-kinase anchor protein AKAP121 is a negative regulator of cardiomyocyte hypertrophy. J. Mol. Cell. Cardiol. 46:674-81
142. Perrino C, Feliciello A, SchiattarellaGG, EspositoG, Guerriero R, et al. 2010.AKAP121 downregulation impairs protective cAMP signals, promotes mitochondrial dysfunction, and increases oxidative stress. Cardiovasc. Res. 88:101-10
143. Cardone L, Carlucci A, Affaitati A, Livigni A, DeCristofaro T, et al. 2004. Mitochondrial AKAP121 binds and targets protein tyrosine phosphatase D1, a novel positive regulator of src signaling. Mol. Cell. Biol. 24:4613-26
144. Livigni A, Scorziello A, Agnese S, Adornetto A, Carlucci A, et al. 2006. Mitochondrial AKAP121 links cAMP and src signaling to oxidative metabolism. Mol. Biol. Cell 17:263-71
145. Carlucci A, Adornetto A, Scorziello A, Viggiano D, Foca M, et al. 2008. Proteolysis ofAKAP121 regulates mitochondrial activity during cellular hypoxia and brain ischaemia. EMBO J. 27:1073-84
146. Kim H, Scimia MC, Wilkinson D, Trelles RD, Wood MR, et al. 2011. Fine-tuning of Drp1/Fis1 availability by AKAP121/Siah2 regulates mitochondrial adaptation to hypoxia. Mol. Cell 44:532-44
147. Acin-Perez R, Salazar E, Kamenetsky M, Buck J, Levin LR, Manfredi G. 2009. Cyclic AMP produced inside mitochondria regulates oxidative phosphorylation. Cell Metab. 9:265-76
148. Means CK, Xiao CY, Li Z, Zhang T, Omens JH, et al. 2007. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 292:H2944-51
149. Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, et al. 2003. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 22:5491-500
150. Johnson KR, Becker KP, Facchinetti MM, Hannun YA, Obeid LM. 2002. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane: extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J. Biol. Chem. 277:35257-62
151. Lacana E, Maceyka M, Milstien S, Spiegel S. 2002. Cloning and characterization of a protein kinase A anchoring protein (AKAP)-related protein that interacts with and regulates sphingosine kinase 1 activity. J. Biol. Chem. 277:32947-53
152. Scholten A, Poh MK, van Veen TA, van Breukelen B, Vos MA, Heck AJ. 2006. Analysis of the cGMP/cAMP interactome using a chemical proteomics approach in mammalian heart tissue validates sphingosine kinase type 1-interacting protein as a genuine and highly abundant AKAP. J. Proteome Res. 5:1435-47
153. Scholten A, vanVeen TA, VosMA, Heck AJ. 2007. Diversity of cAMP-dependent protein kinase isoforms and their anchoring proteins in mouse ventricular tissue. J. Proteome Res. 6:1705-17
154. Aye TT, Soni S, van Veen TA, van derHeyden MA, Cappadona S, et al. 2012. Reorganized PKA-AKAP associations in the failing human heart. J. Mol. Cell. Cardiol. 52:511-18
155. Kovanich D, van der Heyden MA, Aye TT, van Veen TA, Heck AJ, Scholten A. 2010. Sphingosine kinase interacting protein is an A-kinase anchoring protein specific for type I cAMP-dependent protein kinase. ChemBioChem 11:963-71
156. Darshi M, Mendiola VL, Mackey MR, Murphy AN, Koller A, et al. 2010. ChChd3, an inner mitochondrial membrane protein, is essential for maintaining crista integrity and mitochondrial function. J. Biol. Chem. 286:2918-32
157. Nauert JB, Klauck TM, Langeberg LK, Scott JD. 1997. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr. Biol. 7:52-62
158. Dransfield DT, Bradford AJ, Smith J, Martin M, Roy C, et al. 1997. Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J. 16:35-43
159. Coghlan VM, Langeberg LK, Fernandez A, Lamb NJC, Scott JD. 1994. Cloning and characterization of AKAP 95, a nuclear protein that associates with the regulatory subunit of type II cAMP-dependent protein kinase. J. Biol. Chem. 269:7658-65
160. Li H, Adamik R, Pacheco-Rodriguez G, Moss J, Vaughan M. 2003. Protein kinase A-anchoring (AKAP) domains in brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2). Proc. Natl. Acad. Sci. USA 100:1627-32
161. Lester LB, Coghlan VM, Nauert B, Scott JD. 1996. Cloning and characterization of a novel A-kinase anchoring protein: AKAP 220, association with testicular peroxisomes. J. Biol. Chem. 271:9460-65
162. Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, et al. 2011. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. Mol. Cell 42:84-95
163. Hanoune J, Defer N. 2001. Regulation and role of adenylyl cyclase isoforms. Annu. Rev. Pharmacol. Toxicol. 41:145-74
164. Mosenden R, Tasḱen K. 2011. Cyclic AMP-mediated immune regulation-overview of mechanisms of action in T cells. Cell. Signal. 23:1009-16
165. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, et al. 2007. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445:771-75
166. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, et al. 2007. Cyclic adenosinemonophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 204:1303-10
167. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, et al. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp.Med. 204:1257-65
168. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. 2004. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J. Virol. 78:2454-59
169. Aandahl EM, Quigley MF, Moretto WJ, Moll M, Gonzalez VD, et al. 2004. Expansion of CD7low and CD7negative CD8T-cell effector subsets inHIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. Blood 104:3672-78
170. Johansson CC, Bryn T, Aandahl EM, AreklettMA, Aukrust P, et al. 2004. Treatmentwith type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected patients on highly active antiretroviral therapy. AIDS 18:951-52
171. Mahic M, Yaqub S, Johansson CC, Tasḱen K, Aandahl EM. 2006. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J. Immunol. 177:246-54
172. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Horejsi V, et al. 2001. Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts. J. Biol. Chem. 276:29313-18
173. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, et al. 2004. TCR-and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J. Immunol. 173:4847-58
174. Aandahl EM, Moretto WJ, Haslett PA, Vang T, Bryn T, et al. 2002. Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J. Immunol. 169:802-8
175. Skalhegg BS, Tasḱen K, Hansson V, Huitfeldt HS, Jahnsen T, Lea T. 1994. Location of cAMPdependent protein kinase type I with the TCR-CD3 complex. Science 263:84-87
176. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, et al. 2008. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol. Immunother. 57:813-21
177. Skalhegg BS, Landmark BF, Doskeland SO, HanssonV, Lea T, Jahnsen T. 1992. Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3′, 5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J. Biol. Chem. 267:15707-14
178. Levy FO, Rasmussen AM, Tasḱen K, Skalhegg BS, Huitfeldt HS, et al. 1996. Cyclic AMP-dependent protein kinase (cAK) in human B cells: co-localization of type I cAK (RIα2C2) with the antigen receptor during anti-immunoglobulin-induced B cell activation. Eur. J. Immunol. 26:1290-96
179. Torgersen KM, Vaage JT, Levy FO, Hansson V, Rolstad B, Tasḱen K. 1997. Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity. J. Biol. Chem. 272:5495-500
180. Vang T, Abrahamsen H, Myklebust S, Horejsi V, Tasḱen K. 2003. Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase A inhibits T cell receptor signaling. J. Biol. Chem. 278:17597-600
181. VangT, Torgersen KM, Sundvold V, Saxena M, Levy FO, et al. 2001. Activation of theCOOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J. Exp. Med. 193:497-507
182. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasḱen K. 2002. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell. Signal. 14:1-9
183. Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, et al. 2000. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase Csk and is involved in regulation of T cell activation. J. Exp. Med. 191:1591-604
184. Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, et al. 2000. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 404:999-1003
185. Takeuchi S, Takayama Y, Ogawa A, Tamura K, Okada M. 2000. Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk. J. Biol. Chem. 275:29183-86
186. Aandahl EM, Aukrust P, Muller F, Hansson V, Tasḱen K, Froland SS. 1999. Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART. AIDS 13:F109-14
187. Aukrust P, Aandahl EM, Skalhegg BS, Nordoy I, Hansson V, et al. 1999. Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J. Immunol. 162:1178-85
188. Holm AM, Aukrust P, Aandahl EM, Muller F, Tasḱen K, Froland SS. 2003. Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency-involvement of protein kinase A type I. J. Immunol. 170:5772-77
189. Brudvik KW, Henjum K, Aandahl EM, Bjørnbeth BA, Tasḱen K. 2012. Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. Cancer Immunol. Immunother. 61:1045-53
190. Gold MG, Smith FD, Scott JD, Barford D. 2008. AKAP18 contains a phosphoesterase domain that binds AMP. J. Mol. Biol. 375:1329-43
191. Robinson CV, Sali A, Baumeister W. 2007. The molecular sociology of the cell. Nature 450:973-82
192. Heck AJ. 2010. At the interface of interaction proteomics and structural biology. Mol. Cell. Proteomics 9:1633
193. Gonen T, Cheng Y, Sliz P, Hiroaki Y, Fujiyoshi Y, et al. 2005. Lipid-protein interactions in doublelayered two-dimensional AQP0 crystals. Nature 438:633-38
194. Jain A, Liu R, Ramani B, Arauz E, Ishitsuka Y, et al. 2011. Probing cellular protein complexes using single-molecule pull-down. Nature 473:484-88
195. Hoshi N, Langeberg LK, Gould CM, Newton AC, Scott JD. 2010. Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol. Cell 37:541-50
196. Hoshi N, Langeberg LK, Scott JD. 2005. Distinct enzyme combinations in AKAP signalling complexes permit functional diversity. Nat. Cell Biol. 7:1066-73
197. Prince JT, Ahn NG. 2010. The case of the disappearing drug target. Mol. Cell 37:455-56
198. Christian F, Szaszak M, Friedl S, Drewianka S, Lorenz D, et al. 2011. Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J. Biol. Chem. 286:9079-96